Oncolytics Biotech (ONCY) Consolidated Net Income (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Consolidated Net Income of -$10.8 million for Q3 2025, down 55.2% year-over-year from -$24.2 million in Q3 2024, and down 127.29% quarter-over-quarter from -$4.8 million in Q2 2025.
Oncolytics Biotech (ONCY) Consolidated Net Income (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Consolidated Net Income for 17 consecutive years, with -$10.8 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Consolidated Net Income fell 55.2% year-over-year to -$10.8 million; the TTM figure through Dec 2025 stood at -$15.6 million (up 12.64% YoY), while the FY2025 annual figure was -$28.8 million, down 25.2% from the prior year.
- Consolidated Net Income retreated to -$10.8 million in Q3 2025 per ONCY's latest filing, from -$4.8 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $5.9 million in Q2 2021 and bottomed at -$37.8 million in Q4 2023.
- Historically, Consolidated Net Income has averaged -$8.4 million across 5 years, with a median of -$5.2 million in 2024.
- On a YoY basis, Consolidated Net Income climbed as much as 217.99% in 2021 and fell as far as 230.26% in 2021.
- Oncolytics Biotech's Consolidated Net Income stood at -$35.6 million in 2021, then climbed by 15.98% to -$29.9 million in 2022, then declined by 26.16% to -$37.8 million in 2023, then jumped by 84.89% to -$5.7 million in 2024, then tumbled by 89.8% to -$10.8 million in 2025.
- Business Quant data shows ONCY's Consolidated Net Income at -$10.8 million in Q3 2025, -$4.8 million in Q2 2025, and -$5.7 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | -9.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.44 Mn |
| Sep 30, 2025 | -10.83 Mn |
| Jun 30, 2025 | -4.76 Mn |
| Dec 31, 2024 | -5.71 Mn |
| Sep 30, 2024 | -6.98 Mn |
| Jun 30, 2024 | -5.17 Mn |
| Dec 31, 2023 | -37.77 Mn |
| Sep 30, 2023 | -7.32 Mn |
| Jun 30, 2023 | -5.58 Mn |
| Mar 31, 2023 | 4.76 Mn |
| Dec 31, 2022 | -29.94 Mn |
| Sep 30, 2022 | -3.17 Mn |
| Jun 30, 2022 | -3.89 Mn |
| Mar 31, 2022 | 5.39 Mn |
| Dec 31, 2021 | -35.64 Mn |
| Sep 30, 2021 | 3.80 Mn |
| Jun 30, 2021 | 5.93 Mn |
| Mar 31, 2021 | -5.12 Mn |
| Dec 31, 2020 | 27.36 Mn |
| Sep 30, 2020 | -5.12 Mn |